Suppr超能文献

与基于电子病历的 COVID-19 后急性后遗症定义相关的因素:系统性自身免疫性风湿病患者。

Factors Associated With an Electronic Health Record-Based Definition of Postacute Sequelae of COVID-19 in Patients With Systemic Autoimmune Rheumatic Disease.

机构信息

N.J. Patel, MD, MPH, Z.S. Wallace, MD, MSc, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, and Harvard Medical School, and Rheumatology and Allergy Clinical Epidemiology Research Center, Mongan Institute, Department of Medicine, Massachusetts General Hospital.

X. Wang, MS, E.N. Kowalski, BS, K.M.M. Vanni, BA, G. Qian, BA&Sc, K.J. Bade, BS, A. Saavedra, BA, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital.

出版信息

J Rheumatol. 2024 May 1;51(5):529-537. doi: 10.3899/jrheum.2023-1092.

Abstract

OBJECTIVE

Many individuals with rheumatic disease are at higher risk for severe acute coronavirus disease 2019 (COVID-19). We aimed to evaluate risk factors for postacute sequelae of COVID-19 (PASC) using an electronic health record (EHR)-based definition.

METHODS

We identified patients with prevalent rheumatic diseases and COVID-19 within the Mass General Brigham healthcare system. PASC was defined by the International Classification of Diseases, 10th revision (ICD-10) codes, relevant labs, vital signs, and medications at least 30 days following the first COVID-19 infection. Patients were followed until the earliest of incident PASC, repeat COVID-19 infection, 1 year of follow-up, death, or February 19, 2023. We used multivariable Cox regression to estimate the association of baseline characteristics with PASC risk.

RESULTS

Among 2459 patients (76.37% female, mean age 57.4 years), the most common incident PASC manifestations were cough (14.56%), dyspnea (12.36%), constipation (11.39%), and fatigue (10.70%). Serious manifestations including acute coronary disease (4.43%), thromboembolism (3.09%), hypoxemia (3.09%), stroke (1.75%), and myocarditis (0.12%) were rare. The Delta wave (adjusted hazard ratio [aHR] 0.63, 95% CI 0.49-0.82) and Omicron era (aHR 0.50, 95% CI 0.41-0.62) were associated with lower risk of PASC than the early pandemic period (March 2020-June 2021). Age, obesity, comorbidity burden, race, and hospitalization for acute COVID-19 infection were associated with greater risk of PASC. Glucocorticoid (GC) use (aHR 1.19, 95% CI 1.05-1.34 compared to no use) was associated with greater risk of PASC.

CONCLUSION

Among patients with rheumatic diseases, following their first COVID-19 infection, we found a decreased risk of PASC over calendar time using an EHR-based definition. Aside from GCs, no specific immunomodulatory medications were associated with increased risk, and risk factors were otherwise similar to those seen in the general population.

摘要

目的

许多患有风湿性疾病的个体患严重急性 2019 冠状病毒病(COVID-19)的风险较高。我们旨在使用基于电子健康记录(EHR)的定义评估 COVID-19 后后遗症(PASC)的风险因素。

方法

我们在马萨诸塞州综合医院系统中确定了患有常见风湿性疾病和 COVID-19 的患者。PASC 通过国际疾病分类,第 10 版(ICD-10)代码、相关实验室检查、生命体征和至少 30 天后 COVID-19 感染后的药物来定义。患者随访至最早发生 PASC、重复 COVID-19 感染、1 年随访、死亡或 2023 年 2 月 19 日。我们使用多变量 Cox 回归来估计基线特征与 PASC 风险的关系。

结果

在 2459 名患者(76.37%为女性,平均年龄 57.4 岁)中,最常见的 PASC 表现为咳嗽(14.56%)、呼吸困难(12.36%)、便秘(11.39%)和疲劳(10.70%)。包括急性冠状动脉疾病(4.43%)、血栓栓塞(3.09%)、低氧血症(3.09%)、中风(1.75%)和心肌炎(0.12%)在内的严重表现较为少见。与早期大流行时期(2020 年 3 月至 2021 年 6 月)相比,Delta 波(调整后的危险比[aHR]0.63,95%置信区间[CI]0.49-0.82)和奥密克戎时代(aHR 0.50,95%CI 0.41-0.62)与 PASC 风险降低相关。年龄、肥胖、合并症负担、种族和因急性 COVID-19 感染住院与 PASC 风险增加相关。与未使用相比,糖皮质激素(GC)使用(aHR 1.19,95%CI 1.05-1.34)与 PASC 风险增加相关。

结论

在患有风湿性疾病的患者中,我们发现使用基于 EHR 的定义,随着时间的推移,COVID-19 后的 PASC 风险降低。除了 GC 之外,没有特定的免疫调节药物与风险增加相关,并且风险因素与一般人群中的风险因素相似。

相似文献

本文引用的文献

5
High risk of autoimmune diseases after COVID-19.感染新冠后患自身免疫性疾病的风险增加。
Nat Rev Rheumatol. 2023 Jul;19(7):399-400. doi: 10.1038/s41584-023-00964-y.
7
COVID-19 and antiphospholipid antibodies.COVID-19 与抗磷脂抗体。
Best Pract Res Clin Haematol. 2022 Sep;35(3):101402. doi: 10.1016/j.beha.2022.101402. Epub 2022 Oct 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验